\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationOnline
ProgrammesThe European Commission and the European Committee of the Regions will organize on 28 March 2023 the High Level Event of the Partnerships for Regional Innovation (PRI) “From playbook to implementation” as a bridge between smart specialisation and other EU policies to promote innovation-driven territorial transformation.
Participants to this event will include the Presidents and Regional Ministers of the 74 territories, who will accompany Commissioner Gabriel, Commissioner Ferreira and the President of the European Committee of the Region, Alves Cordeiro in this event.
At the scientific level, the event will gather world-leading experts in place-based innovation and territorial development through the PRI Scientific Committee.
More information on the programme and event can be found here.
This event will be livestreamed through this link. Registration for the livestream is not required.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
